High-risk patients typically receive post-chemotherapy treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) to prevent, alleviate, and shorten agranulocytosis, thereby reducing the risk of infection and fever (Rattay and Benndorf, 2021). This evidence concerns the gene CSF3 and infection.